HYMPAVZI® (marstacimab-hncq) is a laboratory-engineered monoclonal antibody that targets an anticoagulant protein known as tissue factor pathway inhibitor. It is administered subcutaneously once a week using a pen-like device.

MASAC recommends routine iron screening for people with bleeding disorders to detect iron deficiency early and improve care.

Government Relations Update: May 2026 | Key advocacy, policy, and funding updates affecting the bleeding disorders community.

FED UP Act aims to improve diagnosis, care, and research equity for women and girls with bleeding disorders.

Government Relations Update: April 2026 | Key advocacy, policy, and funding updates affecting the bleeding disorders community.

Jacob Murdock will lead NBDF Nevada and Nebraska, boosting collaboration, efficiency, and support for bleeding disorders.

Combined chapter will expand support, education, and advocacy for Idaho’s bleeding disorders community